Tirzepatide
Dual GIP/GLP-1 receptor agonist referenced in metabolic and incretin research literature. For laboratory research use.
What the literature says.
Mechanism of action
Activates both GIP and GLP-1 receptors, producing additive incretin signaling in beta-cell and CNS models. The C20 fatty-diacid side chain extends plasma half-life via albumin binding.
Preclinical summary
Tirzepatide is a 39-amino-acid synthetic peptide engineered as a dual incretin receptor co-agonist. Preclinical and clinical literature covers glycemic and weight-related endpoints.
Safety
Research material only. Not a drug, supplement, or food product. No human or animal administration is supported or implied. Handling should follow the purchaser's institutional biosafety and chemical hygiene protocols.
Shipping & storage
Ships overnight in insulated packaging with ice packs when lab conditions require. Store lyophilized powder at 2–8°C. After reconstitution, store at 2–8°C and use within standard stability windows documented on the lot-specific Certificate of Analysis.
The compound, in numbers.
Research use only.
These products are intended for laboratory research purposes only and are not for human or animal consumption.
The statements on this website have not been evaluated by the U.S. Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
